Duo Inhibitors

Imatinib inhibits BCR-ABL tyrosine kinase, preventing its action in chronic myeloid leukemia (CML) and some other cancers. BCR-ABL is a hybrid gene formed by a chromosome rearrangement, and its product continuously signals cells to divide. Imatinib blocks this aberrant signaling, thwarting the progression of leukemia.

Sorafenib targets and inhibits several tyrosine protein kinases, such as VEGFR, PDGFR, and Raf family kinases, which are implicated in tumor growth and angiogenesis. By inhibiting these kinases, sorafenib impedes tumor growth, proliferation, and vascularization, thus limiting the nutrient supply to the tumor cells and obstructing their growth and survival pathways.

Lapatinib is a dual inhibitor of EGFR and HER2/neu tyrosine kinases, interrupting their downstream signal transduction and thereby inhibiting tumor cell proliferation and inducing apoptosis in EGFR and/or HER2/neu-expressing carcinoma cells. By blocking these receptors, lapatinib disrupts multiple signaling pathways that contribute to tumor cell growth and survival.

Vandetanib inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors and epidermal growth factor (EGF) receptors, which are implicated in the pathogenesis of cancer through promoting angiogenesis and tumor cell proliferation and migration. Thus, vandetanib disrupts multiple aspects of tumor growth and metastasis.

Regorafenib is a multi-kinase inhibitor that targets angiogenic (VEGFR1, VEGFR2, VEGFR3), stromal (PDGFR, FGFR), and oncogenic (KIT, RET, RAF-1, BRAF) receptor tyrosine kinases. By inhibiting these kinases, regorafenib disrupts tumor microenvironment, growth, and progression by affecting both tumor cells and the tumor stroma.

Sunitinib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, which are involved in tumor growth, angiogenesis, and tumor progression. By blocking these receptors, sunitinib interferes with the vascularization, growth, and spread of tumor cells, primarily through the inhibition of tumor vascularization and direct effects on tumor cell proliferation.

Nilotinib inhibits the BCR-ABL kinase, which is a constitutively active kinase that promotes CML. It specifically targets the ATP-binding site of the kinase, thereby preventing the transfer of a phosphate group to the substrate, which blocks the signaling for cell proliferation and induces apoptosis in BCR-ABL-positive cells, thus limiting the progression of leukemia.

Dasatinib is a broad-spectrum multi-targeted kinase inhibitor that inhibits BCR-ABL and Src family kinases, among others. It prevents BCR-ABL-mediated continuous proliferation signal, and Src-mediated survival and adhesion signaling in leukemia cells. By interrupting these signaling pathways, dasatinib inhibits leukemia cell proliferation and induces apoptosis.

Pazopanib inhibits multiple receptor tyrosine kinases, including VEGFR, PDGFR, and c-KIT, which are involved in tumor angiogenesis and tumor cell proliferation. By inhibiting these kinases, pazopanib disrupts the blood supply and nutrient availability to the tumor cells, suppressing their growth and proliferation.

Lenvatinib inhibits VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT, thus obstructing the pathways responsible for tumor angiogenesis and progression. By inhibiting these kinases, lenvatinib disrupts tumor vascularization and impacts multiple signaling pathways involved in tumor cell proliferation, survival, and metastasis.